Natasha B. Leighl, MD, BSc, MMSc, clinician investigator and member of the  Cancer Clinical Research Unit (CCRU) at Princess Margaret Cancer Centre, discusses patient satisfaction and resource utilization results from the phase 3 PALOMA-3 study (NCT05388669).

Dr Leighl on Patient Satisfaction and Resource Utilization From PALOMA-3 in NSCLC

Natasha B. Leighl, MD, BSc, MMSc, clinician investigator and member of the Cancer Clinical Research Unit (CCRU) at Princess Margaret Cancer Centre, discusses patient satisfaction and resource utilization results from the phase 3 PALOMA-3 study (NCT05388669).

PALOMA-3 compared subcutaneous (SC) amivantamab-vmjw (Rybrevant) with intravenous (IV) administration of the agent, both in combination with lazertinib (Lazcluze) in patients with locally advanced or metastatic non­–small cell lung cancer (NSCLC) with documented 

 exon 19 deletions or L858R substitution mutations. The 

combination was approved by the FDA in this patient population

Findings from PALOMA-3 presented during the 

2024 IASLC World Conference on Lung Cancer

 showed that SC amivantamab met the noninferiority criteria for pharmacokinetic end points and objective response rate. In terms of efficacy the hazard ratios for progression-free survival and overall survival were 0.84 (95% CI, 0.64-1.10; 

 =.02), respectively. Additionally, patients who received SC amivantamab (n = 198) experienced a significantly decreased time in chair compared with those who received the IV formulation (n = 198) on day 1 of cycle 1, at 0.4 hours vs 6.5 hours, respectively, Leighl says. On day 1 of cycle 3, these figures were 0.6 hours vs 3.4 hours, in the SC (n = 163) and IV (n = 147) arms, respectively.

Health care resource utilization was also decreased with SC amivantamab vs the IV formulation, Leighl notes. On day 1 of cycle 1, SC administration led to a median active health care provider time of 5.6 hours compared with 7.6 hours for IV administration; these figures were 2.3 hours vs 4.4 hours on day 1 of cycle 3, respectively. Median patient time in the treatment room was also decreased with SC amivantamab vs IV administration, Leighl adds. On day 1 of cycle 1, patients in the SC group had a median time in the treatment room of 4.7 hours compared 7.0 hours in the IV group. These times were 1.5 hours vs 3.9 hours on day 1 of cycle 3, respectively.

Videos

Natasha B. Leighl, MD, BSc, MMSc, discusses patient satisfaction and resource utilization results from the phase 3 PALOMA-3 study.

Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial

 Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial

Dr. Natasha Leighl presents the primary results of the phase 3, randomized controlled PALOMA-3 (NCT05388669) trial assessing the overall survival and non-inferiority of subcutaneous amivantamab compared to intravenous amivantamab, in combination with lazertinib, in patients with refractory EGFR-mutated, advanced non-small cell lung cancer. 

Subcutaneous Amivantamab vs Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory EGFR-Mutated, Advanced Non-Small Cell Lung Cancer (NSCLC): Primary Results, Including Overall Survival (OS), From the Global, Phase 3, Randomized Controlled PALOMA-3 Trial

Natasha B Leighl, MD, BSc, MMSc

Articles

Dr Leighl on Patient Satisfaction and Resource Utilization From PALOMA-3 in NSCLC

Subcutaneous Amivantamab vs Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory EGFR-Mutated, Advanced Non-Small Cell Lung Cancer (NSCLC): Primary Results, Including Overall Survival (OS), From the Global, Phase 3, Randomized Controlled PALOMA-3 Trial